

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

50-587 / S-046

Trade Name: Primaxin IV for Injection

Generic Name: Imipenem and Cilastatin

Sponsor: Merck & Co.

Approval Date: September 19, 1996

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

50-587 / S-046

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

50-587 / S-046

APPROVAL LETTER

NDA 50-587/S-046

SEP 19 1996

Dr. Henrietta N. Ukwu
Director
Regulatory Liasion
Merck & Company, Inc.
P.O. Box 4, BLA-30A
West Point PA 19486-0004

Dr. Ukwu:

Reference is made to your supplemental New Drug Application (NDA) dated August 6, 1996 submitted pursuant to Section 507 of the Federal Food, Drug, and Cosmetic Act for Primaxin I.V. (Imipenem Cilastatin Sodium for Injection) 400ug/mg.

The supplemental application provides for a switch from use of in-house manufactured

We have completed our review of this supplemental application and it is approved effective as of the date of this letter.

This approval affects only those changes specifically submitted in this supplemental application. Other changes that may have been approved or are pending evaluation are not affected.

We remind you that you must comply with the requirements set forth under 21 CFR 314.80 and 314.81 for an approved NDA.

Sincerely yours,

Bonnie B. Dunn, Ph.D.
Chemistry Team Leader (Acting) DNDCIII
Division of Anti-Infective Drug Products (HFD-520)
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

cc: Orig NDA 50-587

HFD-830/Sheinin

HFD-520/Div. File

HFD-130/JAllen

HFD-520/PHARM/Buko

HFD-520/MICRO/Sheldon

HFD-520/MO/Thompson

HFD-520/CHEM/Katague

HFD-520/TL (Acting) BDunn:R/D initialed

APPROVED

*ASD
9/18/96*


CHEMIST'S REVIEW	1. ORGANIZATION DAIDP (HFD-520)	2. NDA NUMBER 50-587
3. NAME & ADDRESS OF APPLICANT Merck & Company, Inc. P.O. Box 4, BLA-30A West Point, PA 19486	4. AF NUMBER	
5. SUPPLEMENT (s) NUMBER (s) DATE (s) SCM-046 8/6/96		

6. NAME OF DRUG Primaxin I.V.	7. NONPROPRIETARY NAME Imipenem-Cilastatin Na for Injection
8. SUPPLEMENT (s) PROVIDES FOR: S-046: A switch from use of in-house manufactured	
9. AMENDMENTS AND OTHER (REPORTS, etc.) DATES	

10. PHARMACOLOGICAL CATEGORY Antibacterial	11. HOW DISPENSED XXX Rx OTC	12. RELATED IND/NDA/DMF (s) DMF 4318
13. DOSAGE FORM (s) I.V.	14. POTENCY (ies) 400 ug/mg	


15. CHEMICAL NAME AND STRUCTURE

Imipenem



$C_{12}H_{17}N_3O_4 \cdot H_2O$ 317.37
 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, monohydrate, [5R-[5 α ,6 α (R*)]]-.
 (5R,6S)-3-[[2-(Formimidoylamino)ethyl]thio]-6-[(R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate [74431-23-5].
 Anhydrous 299.34 [64221-86-9].

Cilastatin Sodium



$C_{16}H_{25}N_2NaO_5S$ 380.44
 2-Heptenoic acid, 7-[[2-amino-2-carboxyethyl]thio]-2-[[2,2-dimethylcyclopropyl]carbonyl]amino]-, monosodium salt, [R-[R*,S*-(Z)]]-.
 Sodium (Z)-7-[[2-[(R)-2-amino-2-carboxyethyl]thio]-2-[(S)-2,2-dimethylcyclopropanecarboxamido]-2-heptenoate [81129-83-1].

16. RECORDS AND REPORTS

CURRENT	Yes	No
REVIEWED	Yes	No

17. COMMENTS

In support of this application, the sponsor submitted comparative data for _____ e HCl made in house and from those _____. In addition test data are provided on Imipenem Nonsterile manufactured using both Merck and purchased _____. Also attached is an acceptable EER for ISP dated 8/28/96. See attached pages for detailed comments.

18. **CONCLUSIONS AND RECOMMENDATIONS**

Recommend approval letter to issue for this supplement.

cc: Orig: NDA 50-587

HFD-520

HFD-520/MO/Thompson

HFD-520/Pharm/Osterberg

HFD-520/CSO/Roche

HFD-520/DBKatague

HFD-830/BDunn:R/D initialed. *BBD 9/13/96*

19.

REVIEWER

NAME

SIGNATURE

DATE COMPLETED

David B. Katague, Ph.D.

David B. Katague

9/10/96

DISTRIBUTION

ORIGINAL JACKET

REVIEWER

DIVISION FILE

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

50-587 / S-046

CHEMISTRY REVIEW(S)